Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

This trial is comparing two immunotherapy-based combination treatments for people with advanced liver cancer (hepatocellular carcinoma, or HCC) that cannot be surgically removed. One combination uses SHR-8068, adebrelimab, and bevacizumab; the other uses sintilimab and bevacizumab. Both are immunotherapy-plus-anti-angiogenic combinations, and the study is looking at which is more effective and safer as a first-line treatment. **You may be eligible if...** - You are 18 or older - You have been confirmed to have advanced or metastatic liver cancer (HCC) that cannot be surgically removed - You have at least one measurable tumor - You have not received any prior systemic treatment for your liver cancer - Your liver function is adequate (Child-Pugh score A or B7) and ECOG performance score is 0–1 - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You have mixed liver cancer types (e.g., cholangiocarcinoma combined with HCC) - You have had prior systemic therapy for HCC - You have serious bleeding risks or uncontrolled high blood pressure Talk to your doctor to see if this trial is right for you.